First-in-human results of terbium-161 [Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study.

Background: Terbium-161 (Tb) emits beta-radiation similar to lutetium-177 (Lu), with additional radiation over ultra-short path lengths from Auger electrons. Tb has shown superior in-vitro and in-vivo efficacy compared with Lu. We aimed to evaluate the safety of [Tb]Tb-PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC).